Introduction
Chlamydia pneumoniae was first described as a respiratory tract pathogen in 1986. 1 Although its mode of transmission remains uncertain, it is probably spread via infected respiratory secretions. The proportion of community-acquired pneumonias associated with C. pneumoniae infection has been estimated to be 6-22%, depending upon geographical location, age group and the diagnostic methods used. 2 There is evidence that C. pneumoniae is associated with other respiratory infections, including acute exacerbations of chronic bronchitis, otitis media, sinusitis and reactive airway disease. [3] [4] [5] In addition, persistent nasopharyngeal infection with C. pneumoniae has been documented for up to several years in adults following acute respiratory infection. 6, 7 Chronic infection with C. pneumoniae has also been implicated in the pathogenesis of atherosclerosis, although this is still very controversial. 8 The lack of standardized serological and non-culture methods for the detection of this organism has had a significant impact on efforts to study the therapy of C. pneumoniae infection. Most treatment studies have relied entirely on serology for diagnosis, and thus microbiological efficacy has not been established.
C. pneumoniae isolates to a particular quinolone is uniform, usually differing by only one or two dilutions. However, reported susceptibilities can vary as much as ten-fold between different studies. The methods used for testing the susceptibility of C. pneumoniae in vitro have largely been adapted from those used for C. trachomatis. They are not standardized and the results can be influenced by a number of variables, such as the tissue culture system, inoculum size, time of addition of antimicrobial agent, and the number and type of isolates used for testing. There are few studies that have tested large numbers of clinical isolates; many in vitro studies reported in the literature have used fewer than five isolates of C. pneumoniae with many more using only one, most notably TW 183, IOL 207 or laboratory isolates that have been passaged extensively. The results of individual studies of the activity of the newer quinolones are summarized in Table II. 11 -19,21-25 There are limited data available on the potency of gemifloxacin against C. pneumoniae. The two available studies illustrate the discrepancies that exist between different trials. Ridgway et al. 24 tested five isolates of C. pneumoniae (TW 183, IOL 207, 2043 (ATCC VR 1355), TW27.9 and CWL-029 (ATCC VR 1310)) against gemifloxacin and reported an MIC range of 0.06-0.12 mg/L. Subsequently, Roblin et al. 25 tested 20 isolates of C. pneumoniae, including 15 recent clinical isolates from patients enrolled in a USA multicentre study of the treatment of pneumonia with gemifloxacin and other antimicrobials. The MIC 90 and MBC 90 of gemifloxacin were each found to be 0.25 mg/L, which was two-to four-fold higher than the values reported by Ridgway et al. 24 This discrepancy may be within the standard error of the test, secondary to the methods used, or related to variations in the susceptibility of different isolates. The study by Ridgway et al. 24 used McCoy cells, which are ten-to 100-fold less susceptible to C. pneumoniae infection than the HEp-2 cells used by Roblin et al., 25 and this may have led to the lower endpoints. Both studies tested TW 183, but as shown in Table II there was no overlap between the MICs of gemifloxacin against this isolate.
Role of newer quinolones
Although the newer, third-generation quinolones are two-to ten-fold more potent than the older agents against C. pneumoniae, they are still less potent in vitro than the macrolides and tetracyclines. It is unknown whether the potential clinical efficacy of these agents can be extrapolated from the results of in vitro susceptibility testing. Although clarithromycin is ten-to 100-fold more potentthan erythromycin in vitro, it has not been found to be more effective than erythromycin in eradicating C. pneumoniae from the nasopharynx of children with communityacquired pneumonia (eradication rate 79 and 86%, respectively). 26 Considering the enhanced pharmacokinetic profiles and tissue penetration of the newer quinolones, these agents might be expected to be as effective as the macrolides in treating C. pneumoniae infection. However, practically every study published to date on the therapeutic efficacy of quinolones in C. pneumoniae infection has used serology alone for diagnosis, and since this cannot be used to determine microbiological efficacy, the endpoint used for efficacy has been the clinical response.
Clinical efficacy: correlation of in vitro and in vivo activity
A study conducted in 1990 described four patients with bronchitis and pneumonia who received a 10 day course of ofloxacin, and who were retrospectively identified as having serological evidence of acute C. pneumoniae infection (four-fold rise in IgG/IgM titre, single IgM у 16 or IgG у 512). 27 All patients reportedly demonstrated a marked clinical improvement. Based on the MICs of ofloxacin against three laboratory strains (1-2 mg/L), this study concluded that ofloxacin was effective in these patients since the MICs were lower than the achievable serum concentrations. A subsequent study noted a clinical response rate of 83% in patients with community-acquired pneumonia and serological evidence of C. pneumoniae infection who were treated with ofloxacin, compared with 75% in patients who received standard therapy (a -lactam antimicrobial plus a macrolide or tetracycline). 28 Similarly, a further trial reported a clinical cure rate of 98% among patients treated with levofloxacin compared with 93% in those treated with ceftriaxone and/or cefuroxime axetil. 29 In this study, erythromycin or doxycycline could also be added at the investigators' discretion. The response rate Although investigators cannot show eradication if the organism has not been isolated originally, several recent studies have suggested that if a patient with serological evidence of infection improves clinically, the organism can be presumed to be eradicated, even though cultures were not performed. 30, 31 One of these studies compared trovafloxacin and amoxycillin in the treatment of acute exacerbations of chronic bronchitis. 30 The 'eradication' rate in those patients with serological evidence of C. pneumoniae who were treated with amoxycillin was also 100%. Such apparent success with antimicrobial agents that have little or no activity against C. pneumoniae in vitro, such as amoxycillin and cephalosporins, raises a number of questions about the specificity of the serological criteria used to diagnose C. pneumoniae infection.
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There is one anecdotal report of the use of quinolones in C. pneumoniae infection in which cultures were performed. 20 Three patients with culture-documented C. pneumoniae infection (bronchitis and pneumonia) received grepafloxacin, 600 mg po qds for 10-14 days. Two of the three patients remained culture-positive and symptomatic despite 2 weeks of treatment. Of importance, two of these culture-positive patients did not meet the serological criteria for acute C. pneumoniae infection. Preliminary results of two multicentre treatment studies in pneumonia have found that levofloxacin and moxifloxacin had 70-80% efficacy in the eradication of C. pneumoniae from the nasopharynx (M. R. Hammerschlag, unpublished data). These findings are very similar to reported experience with erythromycin, clarithromycin and azithromycin. 26, 32 The MICs and MBCs for C. pneumoniae isolates obtained from patients after treatment were not different from those isolates obtained before treatment, suggesting that persistence was not due to the development of resistance.
Discussion
These studies illustrate several important issues when dealing with the treatment of C. pneumoniae infection, most notably that in vitro activity does not always predict microbiological efficacy.
Although the development of antimicrobial resistance has not yet been described in C. pneumoniae, a four-fold increase in the MIC of azithromycin has been reported in isolates obtained from two patients after therapy with the drug. 26 In addition, resistance to ofloxacin and sparfloxacin has been induced in C. trachomatis after serial passage of the organism in subinhibitory concentrations of these drugs. 9 Therefore, unless cultures are performed more routinely and microbiological efficacy is properly assessed, it will be impossible to survey or document the emergence of resistance in C. pneumoniae.
As the newer quinolones demonstrate activity against both conventional respiratory pathogens and 'atypical' organisms, their inclusion in guidelines for the empirical treatment of community-acquired pneumonia is becoming more common. 33 However, it is important to consider the in vivo microbiological efficacy of the quinolones, and the potential for the development of resistance, when evaluating the clinical utility of these agents in C. pneumoniae infection. Gemifloxacin is one of the more potent newer quinolones. Based on the in vitro data and assuming favourable pharmacokinetics, gemifloxacin should be at least as effective as macrolides against C. pneumoniae in vivo.
